Premarket Biotech Digest – $PRAN announces new publication, $ALXN inks a new deal, $PRTA starts new study

Prana Biotechnology Limited ($PRAN) reported that its article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The company stock soared on the news. The [...]

By |July 6th, 2017|Digest|0 Comments

Premarket Biotech Digest – $SKLN provides update, $BMRN files application, $GSK inks new deal

Centene ($CNC) announced that it will launch its health insurance marketplace product in Missouri in 2018. The company intends to distribute its Ambetter product in 40 counties. 25 of these counties were not expected to have any other insurers available for enrollment. The company [...]

By |July 3rd, 2017|Digest|0 Comments

Premarket Biotech Digest – $PFE receives EU approval, $ALKS announces positive results, $SRNE receives FDA approval

Myovant Sciences Ltd ($MYOV) announced initiating  a Phase 3 clinical program consisting of two international clinical trials, SPIRIT 1 and SPIRIT 2. The trials will evaluate the efficacy and safety of relugolix in women with endometriosis-associated pain. SPIRIT 1 and SPIRIT 2 are randomized, double-blind, [...]

By |June 30th, 2017|Digest|0 Comments

Premarket Biotech Digest – $SPNC acquired by Philips, $DSKX settles litigation, $CEMI inks new deal

ADMA Biologics Inc. ($ADMA) stock shot up as the company announced it is well on its way to get an acquired biologics manufacturing facility back on track. The company CEO Adam Grossman wrote a letter to shareholders stating that Boca Raton, Florida site is [...]

By |June 28th, 2017|Digest|0 Comments

Premarket Biotech Digest – $PTLA receives FDA approval, $KPTI offers updates, $NVO starts new study

Idera Pharmaceuticals Inc. ($IDRA) received a positive boost as the FDA designated its Phase 2-stage IMO-2125 an Orphan Drug for the treatment of Stages IIB to IV melanoma. The  Orphan Drug status in the U.S. offers an additional seven-year period of market exclusivity for [...]

By |June 26th, 2017|Digest|0 Comments

Premarket Biotech Digest – $DMPI receives IRB nod, $PFE slapped with CRL, $PRTO strikes new deal

VistaGen ($VTGN) stock shot up as the company announced the results  two Phase 1 studies of AV-101, a potential candidate for the non-opioid treatment of neuropathic pain. The data showed AV-101 was safe and well-tolerated.  The company said that the data, along with positive [...]

By |June 23rd, 2017|Digest|0 Comments

Premarket Biotech Digest – $SHPG receives FDA approval, $EPZM granted orphan drug status, $RXII completes enrollment

Aimmune Therapeutics ($AIMT) stock showed an uptick as the company announced the update for its late-stage study of peanut allergy candidate AR101. It reported that in a preliminary dataset of 166 European patients who underwent a food challenge to determine eligibility for the Phase [...]

By |June 21st, 2017|Digest|2 Comments

Premarket Biotech Digest – $LLY announces positive results, $IPSEY reports FDA approval, $AMED to pay settlement

Sorrento Therapeutics Inc. ($SRNE) kept up its positive trend as the stock gained another 8 percent in its Friday session. The stock received boost from the company’s recent announcement regarding the lawsuits brought by Wildcat Liquid Alpha, LLC. Sorrento reported that all claims against [...]

By |June 19th, 2017|Digest|0 Comments

Premarket Biotech Digest – $HTGM inks new SOW, $ADMP receives FDA approval, $BMY to sell a unit

Celsion Corporation ($CLSN) stock soared in pre-market trading session as the company announced withdrawing its plan of a stock offering. The company had originally filed on April 5 an S-1 statement with the Securities and Exchange Commission for the sale of shares. The company [...]

By |June 16th, 2017|Digest|0 Comments

Premarket Biotech Digest – $RDHL initiates two products. $BMY starts recall, $PULM inks new deal

RedHill Biopharma ($RDHL) stock perked up as the company announced starting two GI-focused products in the U.S. These products are Donnatal, to be used for the adjunctive treatment of irritable bowel syndrome and EnteraGam, designed for the dietary management of chronic diarrhea and loose [...]

By |June 14th, 2017|Digest|0 Comments

Premarket Biotech Digest – $JNJ receives EU nod, $XBIT terminates trial, $PFE amends protocol

Johnson & Johnson ($JNJ) announced receiving the approval from the regulatory authorities in the EU for its planned $30 billion takeover of Actelion. The approval has come through after the company pledged to spin-off one of the combined firm's two insomnia pipeline programs. Actelion's [...]

By |June 12th, 2017|Digest|0 Comments

Premarket Biotech Digest – $VRX to sell its iNova unit, $MZOR offices raided in Israel, $RHHBY pulls out of licensing deal,

Sophiris Bio ($SPHS) stock zoomed in the pre-market session as the company announced the dosing of its first patient in its Phase 2b clinical trial assessing topsalysin for the treatment of men with localized prostate cancer. The company intends to enroll 40 patients for [...]

By |June 9th, 2017|Digest|0 Comments

Premarket Biotech Digest – $EIGR completes enrollment, $NVO receives EC approval, $INNV in-licenses two products

Eiger BioPharmaceuticals ($EIGR) announced the completion of enrollment for its Phase 2 multiple-ascending dose study assessing subcutaneous exendin 9-39 for the treatment of post-bariatric surgery patients who are experiencing dangerously low postprandial blood glucose levels. The company intends to present the data on June [...]

By |June 7th, 2017|Digest|0 Comments

Premarket Biotech Digest – $LLY announces positive results, $EXAS initiates recall, $BMY inks new collaboration

Halozyme Therapeutics Inc. ($HALO) stock perked up as the company announced the updated results from the Phase 2 HALO-202 study assessing its lead product candidate PEGPH20, combined with Celgene's ABRAXANE (nab-paclitaxel) and gemcitabine (AG), in patients with advanced pancreatic cancer showed a treatment benefit. In [...]

By |June 5th, 2017|Digest|0 Comments

Premarket Biotech Digest –$XBIT announces European study results, $PLX gets FDA nod, $THC modifies agreement

Eleven Biotherapeutics Inc. ($EBIO) announced that its pivotal Phase 3 clinical trial assessing Vicinium in non-muscle invasive bladder cancer exceeded 50% enrollment. The company also said that the trial will proceed without modification as recommended by the independent Data and Safety Monitoring Board.  The [...]

By |June 1st, 2017|Digest|0 Comments

Premarket Biotech Digest – $AVGR announces positive data, $CXRX to be investigated, $CYTX receives BARDA nod,

Microbot Medical Inc. ($MBOT) announced receiving a new patent from the Canadian Intellectual Property Office. The new patent covers the company’s Self-Cleaning Shunt, specifically an inlet head for use on shunts. Microbot has an  exclusive license to the patent from the Technion - Israel [...]

By |June 1st, 2017|Digest|0 Comments

Premarket Biotech Digest – $ISRG receives 501(k) approval, $ZBH suffers recall, $PFE receives EC nod

Quidel Corporation ($QDEL) stock showed strong movement as the company announced receiving the FDA’s 501(k) clearance and Clinical Laboratory Improvements Amendments waiver for its Sofia Influenza A+B Fluorescent Immunoassay  to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid, differential detection [...]

By |May 31st, 2017|Digest|0 Comments

Premarket Biotech Digest – $ECYT to provide update, $CLSN reverse splits stock, $MRK receives Ebola drug approval

Endocyte ($ECYT) reported that it will present updated data on its lead drug candidates EC1456 and EC1169. For EC1456, the results pertain to a  a two-part Phase 1 study, EC1456-01.Part A (dose escalation phase) involves 87 patients with advanced solid tumors while Part B [...]

By |May 30th, 2017|Digest|0 Comments

Premarket Biotech Digest – $TROV reports result, $ANIK enrolls patients, $ABEO receives Orphan Drug status

GlycoMimetics ($GLYC) stock received a positive fillip as the company announced receiving Orphan Drug designation from the European Commission for its GMI-1271 drug candidate for treating acute myeloid leukemia. The drug was also awarded Breakthrough Therapy status for the same indication by the FDA last [...]

By |May 26th, 2017|Digest|0 Comments

Premarket Biotech Digest – $RDUS reports positive results, $RHHBY investigates case, $QDEL receives Japanese approval

Aerie Pharmaceuticals ($AERI) announced positive results from its Phase 3 clinical trial, Mercury 2. The trial compared the efficacy of Roclatan against each of its components, netarsudil and latanoprost, in lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The trial [...]

By |May 25th, 2017|Digest|0 Comments
s2Member®